-
Neuralink receives approval for its first clinical trial in Canada to test its brain chip implant in paralysed individuals.
-
The trial aims to enable individuals with quadriplegia to control digital devices using their thoughts.
-
The study will evaluate the safety and basic functionality of Neuralink’s implant.
Neuralink, founded by Elon Musk, has received approval to conduct its first clinical trial in Canada. The trial will test the safety and functionality of its brain chip implant in individuals with quadriplegia, a condition that causes paralysis of all four limbs. The implant will be surgically placed at Toronto’s University Health Network, and the study will evaluate whether the device can convert brain signals into digital commands, allowing users to interact with external devices such as computers or mobile phones.
This marks a significant milestone for Neuralink, which has previously conducted trials in the United States. In one notable example, a patient with the implant was able to play video games and learn 3D design using only their thoughts. Neuralink’s technology has the potential to restore movement, communication skills, and even vision for disabled patients.
